PASG - Passage Bio Inc. Long-Term Liabilities to Capital

The long-term debt-to-equity ratio dynamics highlight the vulnerability of Passage Bio, Inc. (PASG) due to a narrow market and risks associated with therapy side effects, with the metric holding at 0.00. The business relies on scalable patent vectors for treating rare CNS pathologies. Management is currently strictly prioritizing development, seeking to regain investor confidence through the optimization of R&D expenditures.

Determining the fundamental stability of an asset requires separating long-term obligations from short-term market noise. This indicator measures the ratio of loans with a maturity of more than one year to equity, reflecting the degree of financial leverage. The history of the long-term debt-to-equity ratio shows a current value of 0.00. For Passage Bio, Inc. (PASG), a low debt load is critical when financing costly gene therapy developments, providing the resources necessary to create innovative drugs for CNS pathologies.